Amicus Therapeutics (FOLD) Stock News Today: DMX-200 Trial Milestone, 52-Week High Momentum, and Analyst Forecasts (Dec. 15, 2025)
Amicus Therapeutics, Inc. (Nasdaq: FOLD) is back on investors’ radar as the rare-disease biotech extends a strong 2025 run—helped by a milestone quarter of GAAP profitability, expanding global launches for its Pompe franchise, and fresh news tied to a Phase 3 kidney-disease program it licensed earlier this year. On Monday, December 15, 2025, Amicus shares traded around $10.93 intraday after opening near $10.55, with the session range pushing into the low $11 area. Below is a detailed look at the latest Amicus Therapeutics stock news, what Wall Street is forecasting, and the key catalysts (and risks) investors are weighing as